Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

Nature

Volumn 415, Issue 6869, 2002, Pages 331-335

  Shiver, John W ^a   Fu, Tong Ming ^a   Chen, Ling ^a   Casimiro, Danilo R ^a   Davies, Mary Ellen ^a   Evans, Robert K ^a   Zhang, Zhi Qiang ^a   Simon, Adam J ^a   Trigona, Wendy L ^a   Dubey, Sheri A ^a   Huang, Lingyi ^a   Harris, Virginia A ^a   Long, Romnie S ^a   Liang, Xiaoping ^a   Handt, Larry ^a   Schleif, William A ^a   Zhu, Lan ^a   Freed, Daniel C ^a   Persaud, Natasha V ^a   Guan, Liming ^a   Punt, Kara S ^a   Tang, Aimin ^a   Chen, Minchun ^a   Wilson, Keith A ^a   Collins, Kelly B ^a   Heidecker, Gwendolyn J ^a   Fernandez, V Rose ^a   Perry, Helen C ^a   Joyce, Joseph G ^a   Grimm, Karen M ^a   Cook, James C ^a   Keller, Paul M ^a   Kresock, Denise S ^a   Mach, Henryk ^a   Troutman, Robert D ^a   Isopi, Lynne A ^a   Williams, Donna M ^a   Xu, Zheng ^a   Bohannon, Kathryn E ^a   Volkin, David B ^a   Montefiori, David C ^b   Miura, Ayako ^c   Krivulka, Georgia R ^c   Lifton, Michelle A ^c   Kuroda, Marcelo J ^c   Schmitz, Jörn E ^c   Letvin, Norman L ^c   Caulfield, Michael J ^a   Bett, Andrew J ^a   Youil, Rima ^a   Kaslow, David C ^a   Emini, Emilio A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOLOGY; PROTEINS; VACCINES;

RHESUS MONKEYS;

VIRUSES;

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID DNA; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EXPRESSION VECTOR; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS HYBRID; VIRUS REPLICATION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEFECTIVE VIRUSES; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV INFECTIONS; HIV-1; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VECTORS;

EID: 0037122719     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/415331a     Document Type: Article

References (20)

1. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
2. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
3. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys
4. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men
5. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
6. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: A predominant gag-specific response is associated with nonprogressive infection
7. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression
8. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques
9. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
10. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
11. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
12. Use of nonionic block copolymers in vaccines and therapeutics
13. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys
14. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus
15. Use of major histocompatibility complex class I/peptide/β2 M tetramers to quantitate CD8(+) cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys
16. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
17. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence specific primers and direct sequencing
18. Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors
19. Protective cellular immunity: Cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization
20. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model